Acharya Indira, DeBoer Scott R, Haas Christopher J
Medstar Health Internal Medicine Residency Program, Baltimore, MD, USA.
MedStar Health, MedStar Franklin Square Medical Center, Baltimore, MD, USA.
J Community Hosp Intern Med Perspect. 2024 Jan 12;14(1):43-49. doi: 10.55729/2000-9666.1295. eCollection 2024.
Tissue plasminogen activator (TPA) is indicated as an empiric therapy for refractory out-of-the-hospital cardiac arrest for suspected pulmonary embolism and myocardial infarction. Intracranial hemorrhage following TPA administration is a rare complication resulting in increased morbidity and mortality. A history of intracranial bleed, oral anticoagulant use prior to hospital admission, low body weight, and unstable hypertension with blood pressure above 180/110 mmHg at the time of presentation are associated with intracranial bleeding following tPA administration. Dedicated imaging including a Computed Tomography of the head without contrast, while feasible for patients presenting with acute stroke, is impractical in the setting of cardiac arrest. Here we report a case of 66 years old patient who presented in context of refractory cardiac arrest with recurrent PEAs with interval return of spontaneous circulation (ROSC) and was given tPA with eventual ROSC. He was subsequently found to have both a subarachnoid and intraventricular hemorrhage.
组织型纤溶酶原激活剂(TPA)被用作疑似肺栓塞和心肌梗死导致的院外难治性心脏骤停的经验性治疗方法。使用TPA后发生颅内出血是一种罕见的并发症,会导致发病率和死亡率增加。颅内出血史、入院前使用口服抗凝剂、低体重以及就诊时血压高于180/110 mmHg的不稳定高血压与使用TPA后颅内出血有关。专用成像检查,包括头部非增强计算机断层扫描,虽然对急性中风患者可行,但在心脏骤停情况下并不实用。在此,我们报告一例66岁患者,该患者因难治性心脏骤停伴反复心脏停搏而就诊,期间恢复自主循环(ROSC),并接受了TPA治疗,最终实现ROSC。随后发现他患有蛛网膜下腔出血和脑室内出血。